Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 46 Article 8
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 21, Issue 46, 17 November 2016
News
Weist and Högberg: ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe

+ Author affiliations


Citation style for this article: Weist K, Högberg LD. ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe. Euro Surveill. 2016;21(46):pii=30399. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.46.30399


On the occasion of the European Antibiotic Awareness Day on 18 November 2016, the European Centre for Disease Prevention and Control will release 2015 data on antimicrobial resistance [1] and antimicrobial consumption [2] from 30 European Union (EU) and European Economic Area (EEA) countries. The data are accompanied by summaries highlighting the latest trends [3,4].

The latest data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show high and increasing resistance percentages for Gram-negative bacteria in many parts of Europe. This is reflected by the increase in combined resistance to third-generation cephalosporins, fluoroquinolones and aminoglycosides resistance at EU/EEA level between 2012 and 2015 for both Escherichia coli and Klebsiella pneumoniae. Although carbapenem resistance percentages remained low for most countries in 2015, resistance to carbapenems increased significantly for K. pneumoniae at EU/EEA level over the last four years. Data on polymyxin resistance in EARS-Net are sparse, but some countries, especially those with high percentages of carbapenem resistance, report presence of isolates with polymyxin resistance.

The latest data from the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) showed that overall consumption of antibiotics in the community remained unchanged from 2011 to 2015. However, when measuring the antibiotic consumption as a number of packages per 1,000 inhabitants and per day (used by ESAC-Net as the best available surrogate for prescriptions), six countries experienced a significant decrease during the period the same period.

In the hospital sector, the overall consumption of antibiotics remained stable in the EU/EEA. At the national level, antibiotic consumption of carbapenems and polymyxins used to treat patients with serious multidrug-resistant bacteria is still at a low level compared to the overall consumption of antibiotics for systemic use in the hospital sector. However, significant increasing trends in the consumption of carbapenems (six countries) and polymyxins (eight countries) were reported for the period 2011‒2015.

In countries with high levels of multidrug resistance, including resistance to carbapenems, only a few therapeutic options are available; among these are polymyxins (e.g. colistin). The presence of isolates with resistance to polymyxins and increasing trends in polymyxin consumption in several countries is an important warning that options for the treatment of infected patients are becoming even more limited.



References

  1. European Centre for Disease Prevention and Control (ECDC). Surveillance Atlas of Infectious Diseases. Stockholm: ECDC; 2016. Available from: http://atlas.ecdc.europa.eu/public/ (2015 data will be available from 18 November 2016 9:00 am CET).

  2. European Centre for Disease Prevention and Control (ECDC). Stockholm: ECDC; 2016. Antimicrobial consumption interactive database (ESAC-Net). Internet. Available from: http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/database.aspx (2015 data will be available from 18 November 2016 9:00 am CET).

  3. European Centre for Disease Prevention and Control (ECDC). Summary of the latest data on antibiotic resistance in the European Union 2015. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/eaad/antibiotics-get-informed/antibiotics-resistance-consumption/Pages/data-reports.aspx

  4. European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union 2015. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/eaad/antibiotics-get-informed/antibiotics-resistance-consumption/Pages/data-reports.aspx



Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.